Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 214714, 16 pages
http://dx.doi.org/10.1155/2012/214714
Research Article

Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study

1Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
2Neurochemistry Laboratory, National Parkinson Foundation Centre of Excellence Research Laboratory, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, D-98070 Würzburg, Germany
3Neurobiochemistry Laboratory, Hospital of Child and Adolescent Psychiatry, University of Zürich, CH-8050 Zürich, Switzerland
4Department of Neuropathology, Institute of Pathology, University of Würzburg, D-97080 Würzburg, Germany

Received 27 November 2011; Accepted 4 January 2012

Academic Editor: Carlos Barcia

Copyright © 2012 Pascal. F. Durrenberger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson's disease,” Lancet Neurology, vol. 5, no. 6, pp. 525–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Alves, E. B. Forsaa, K. F. Pedersen, M. D. Gjerstad, and J. P. Larsen, “Epidemiology of Parkinson's disease,” Journal of Neurology, vol. 255, supplement 5, pp. 18–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. S. O'Sullivan, D. R. Williams, D. A. Gallagher, L. A. Massey, L. Silveira-Moriyama, and A. J. Lees, “Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study,” Movement Disorders, vol. 23, no. 1, pp. 101–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Gelb, E. Oliver, and S. Gilman, “Diagnostic criteria for Parkinson disease,” Archives of Neurology, vol. 56, no. 1, pp. 33–39, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Aarsland, J. P. Larsen, N. G. Lim et al., “Range of neuropsychiatric disturbances in patients with Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 67, no. 4, pp. 492–496, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Langston, “The Parkinson's complex: parkinsonism is just the tip of the iceberg,” Annals of Neurology, vol. 59, no. 4, pp. 591–596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Jankovic, “Parkinson's disease: clinical features and diagnosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 4, pp. 368–376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. W. Olanow, M. B. Stern, and K. Sethi, “The scientific and clinical basis for the treatment of Parkinson disease,” Neurology, vol. 72, no. 21, supplement 4, pp. S1–S136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Sulzer, “Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease,” Trends in Neurosciences, vol. 30, no. 5, pp. 244–250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Obeso, M. C. Rodriguez-Oroz, C. G. Goetz et al., “Missing pieces in the Parkinson's disease puzzle,” Nature Medicine, vol. 16, no. 6, pp. 653–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Mandel, T. Fishman, and M. B. Youdim, “Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD,” Parkinsonism and Related Disorders, vol. 13, supplement 3, pp. S242–S247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Hauser, Y. J. Li, H. Xu et al., “Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism,” Archives of Neurology, vol. 62, no. 6, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Zhang, M. James, F. A. Middleton, and R. L. Davis, “Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms,” American Journal of Medical Genetics B, vol. 137, no. 1, pp. 5–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. B. Moran, D. C. Duke, M. Deprez, D. T. Dexter, R. K. Pearce, and M. B. Graeber, “Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease,” Neurogenetics, vol. 7, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. T. G. Lesnick, S. Papapetropoulos, D. C. Mash et al., “A genomic pathway approach to a complex disease: axon guidance and Parkinson disease,” PLoS Genetics, vol. 3, no. 6, article e98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Bossers, G. Meerhoff, R. Balesar et al., “Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death,” Brain Pathology, vol. 19, no. 1, pp. 91–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Grunblatt, S. Mandel, J. Jacob-Hirsch et al., “Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes,” Journal of Neural Transmission, vol. 111, no. 12, pp. 1543–1573, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Cantuti-CastelvetriI, C. Keller-McGandy, B. Bouzou et al., “Effects of gender on nigral gene expression and Parkinson disease,” Neurobiology of Disease, vol. 26, no. 3, pp. 606–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Soreq, Z. Israel, H. Bergman, and H. Soreq, “Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients,” Journal of Neuroimmunology, vol. 201-202, pp. 227–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. R. Scherzer, A. C. Eklund, L. J. Morse et al., “Molecular markers of early Parkinson's disease based on gene expression in blood,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 955–960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Zheng, Z. Liao, J. J. Locascio et al., “PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease,” Science Translational Medicine, vol. 2, no. 52, Article ID 52ra73, 2010. View at Google Scholar
  22. J. E. Bell, I. Alafuzoff, S. Al-Sarraj et al., “Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium,” Acta Neuropathologica, vol. 115, no. 5, pp. 497–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Schroeder, O. Mueller, S. Stocker et al., “The RIN: an RNA integrity number for assigning integrity values to RNA measurements,” BMC Molecular Biology, vol. 7, article 3, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Copois, F. Bibeau, C. Bascoul-Mollevi et al., “Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality,” Journal of Biotechnology, vol. 127, no. 4, pp. 549–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Weng, H. Dai, Y. Zhan, Y. He, S. B. Stepaniants, and D. E. Bassett, “Rosetta error model for gene expression analysis,” Bioinformatics, vol. 22, no. 9, pp. 1111–1121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. P. F. Durrenberger, S. Fernando, S. N. Kashefi et al., “Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study,” Journal of Neuropathology and Experimental Neurology, vol. 69, no. 1, pp. 70–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. G. T. Sutherland, N. A. Matigian, A. M. Chalk et al., “A cross-study transcriptional analysis of Parkinson's disease,” PLoS One, vol. 4, no. 3, Article ID e4955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Danese, E. Dejana, and C. Fiocchi, “Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation,” Journal of Immunology, vol. 178, no. 10, pp. 6017–6022, 2007. View at Google Scholar · View at Scopus
  29. S. Mandel, E. Grunblatt, P. Riederer et al., “Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70,” Annals of the New York Academy of Sciences, vol. 1053, pp. 356–375, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. A. Marchitti, C. Brocker, D. Stagos, and V. Vasiliou, “Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 6, pp. 697–720, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Galter, S. Buervenich, A. Carmine, M. Anvret, and L. Olson, “ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia,” Neurobiology of Disease, vol. 14, no. 3, pp. 637–647, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Marchitti, R. A. Deitrich, and V. Vasiliou, “Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase,” Pharmacological Reviews, vol. 59, no. 2, pp. 125–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Grunblatt, S. Zehetmayer, C. P. Jacob, T. Muller, W. H. Jost, and P. Riederer, “Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease,” Journal Neural Transmission, vol. 117, no. 12, pp. 1387–1393, 2010. View at Publisher · View at Google Scholar
  34. F. M. Jacobs, S. M. Smits, C. W. Noorlander et al., “Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency,” Development, vol. 134, no. 14, pp. 2673–2684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Nunes, L. T. Tovmasian, R. M. Silva, R. E. Burke, and S. P. Goff, “Pitx3 is required for development of substantia nigra dopaminergic neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4245–4250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. S. L. Maxwell, H. Y. Ho, E. Kuehner, S. Zhao, and M. Li, “Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development,” Developmental Biology, vol. 282, no. 2, pp. 467–479, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. R. A. North, “Molecular physiology of P2X receptors,” Physiological Reviews, vol. 82, no. 4, pp. 1013–1067, 2002. View at Google Scholar · View at Scopus
  38. K. Inoue, “Microglial activation by purines and pyrimidines,” Glia, vol. 40, no. 2, pp. 156–163, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. C. G. Schipke, C. Boucsein, C. Ohlemeyer, F. Kirchhoff, and H. Kettenmann, “Astrocyte Ca2+ waves trigger responses in microglial cells in brain slices,” The FASEB Journal, vol. 16, no. 2, pp. 255–257, 2002. View at Google Scholar · View at Scopus
  40. F. Di Virgilio, S. Ceruti, P. Bramanti, and M. P. Abbracchio, “Purinergic signalling in inflammation of the central nervous system,” Trends in Neurosciences, vol. 32, no. 2, pp. 79–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Apolloni, C. Montilli, P. Finocchi, and S. Amadio, “Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events,” The FEBS Journal, vol. 276, no. 2, pp. 354–364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Burnstock, “Purinergic regulation of vascular tone and remodelling,” Autonomic and Autacoid Pharmacology, vol. 29, no. 3, pp. 63–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Suzuki, I. Hide, K. Ido, S. Kohsaka, K. Inoue, and Y. Nakata, “Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia,” Journal of Neuroscience, vol. 24, no. 1, pp. 1–7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Ferrari, C. Pizzirani, E. Adinolfi et al., “The P2X7 receptor: a key player in IL-1 processing and release,” Journal of Immunology, vol. 176, no. 7, pp. 3877–3883, 2006. View at Google Scholar · View at Scopus
  45. A. Kataoka, H. Tozaki-Saitoh, Y. Koga, M. Tsuda, and K. Inoue, “Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT,” Journal of Neurochemistry, vol. 108, no. 1, pp. 115–125, 2009. View at Google Scholar
  46. L. K. Parvathenani, S. Tertyshnikova, C. R. Greco, S. B. Roberts, B. Robertson, and R. Posmantur, “P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease,” The Journal of Biological Chemistry, vol. 278, no. 15, pp. 13309–13317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. F. P. Gendron, M. Chalimoniuk, J. Strosznajder et al., “P2X7 nucleotide receptor activation enhances IFN gamma-induced type II nitric oxide synthase activity in BV-2 microglial cells,” Journal of Neurochemistry, vol. 87, no. 2, pp. 344–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, “Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients,” Neuroscience Letters, vol. 165, no. 1-2, pp. 208–210, 1994. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu, “Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease,” Neuroscience Letters, vol. 211, no. 1, pp. 13–16, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Blum-Degen, T. Müller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer, “Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients,” Neuroscience Letters, vol. 202, no. 1-2, pp. 17–20, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Croisier, L. B. Moran, D. T. Dexter, R. K. Pearce, and M. B. Graeber, “Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition,” Journal of Neuroinflammation, vol. 2, article 14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Gerhard, N. Pavese, G. Hotton et al., “In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease,” Neurobiology of Disease, vol. 21, no. 2, pp. 404–412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Chen, E. Jacobs, M. A. Schwarzschild et al., “Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease,” Annals of Neurology, vol. 58, no. 6, pp. 963–967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. M. K. McCoy and M. G. Tansey, “TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease,” Journal of Neuroinflammation, vol. 5, article 45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Zhang, H. Zhou, B. C. Wilson, J. S. Shi, J. S. Hong, and H. M. Gao, “Fluoxetine protects neurons against microglial activation-mediated neurotoxicity,” Parkinsonism and Related Disorders, vol. 18, supplement 1, pp. S213–S217, 2012. View at Google Scholar
  56. R. Coutinho-Silva, J. L. Perfettini, P. M. Persechini, A. Dautry-Varsat, and D. M. Ojcius, “Modulation of P2Z/P2X(7) receptor activity in macrophages infected with Chlamydia psittaci,” American Journal of Physiology Cell Physiology, vol. 280, no. 1, pp. C81–C89, 2001. View at Google Scholar · View at Scopus
  57. J. G. McLarnon, J. K. Ryu, D. G. Walker, and H. B. Choi, “Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 11, pp. 1090–1097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. J. M. Sanz, P. Chiozzi, D. Ferrari et al., “Activation of microglia by amyloid (beta) requires P2X7 receptor expression,” Journal of Immunology, vol. 182, no. 7, pp. 4378–4385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. L. J. Lawson, V. H. Perry, P. Dri, and S. Gordon, “Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain,” Neuroscience, vol. 3, no. 1, pp. 151–170, 1990. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Marcellino, D. Suarez-Boomgaard, M. D. Sanchez-Reina et al., “On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079,” Journal of Neural Transmission, vol. 117, no. 6, pp. 681–687, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. M. Labasi, N. Petrushova, C. Donovan et al., “Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response,” Journal of Immunology, vol. 168, no. 12, pp. 6436–6445, 2002. View at Google Scholar · View at Scopus
  62. B. Joglar, J. Rodriguez-Pallares, A. L. Rodriguez-Perez, P. Rey, M. J. Guerra, and J. L. Labandeira-Garcia, “The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease,” Journal of Neurochemistry, vol. 109, no. 2, pp. 656–669, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. M. Saavedra, E. Sanchez-Lemus, and J. Benicky, “Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications,” Psychoneuroendocrinology, vol. 36, no. 1, pp. 1–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Muramatsu, R. Kurosaki, H. Watanabe et al., “Cerebral alterations in a MPTP-mouse model of Parkinson's disease—an immunocytochemical study,” Journal Neural Transmission, vol. 110, no. 10, pp. 1129–1144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. D. H. Wright, D. Abran, M. Bhattacharya et al., “Prostanoid receptors: ontogeny and implications in vascular physiology,” American Journal of Physiology, vol. 281, no. 5, pp. R1343–R1360, 2001. View at Google Scholar · View at Scopus
  66. N. A. Dallas, S. Samuel, L. Xia et al., “Endoglin (CD105): a marker of tumor vasculature and potential target for therapy,” Clinical Cancer Research, vol. 14, no. 7, pp. 1931–1937, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. J. F. Santibanez, A. Letamendia, F. Perez-Barriocanal et al., “Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signalling,” Journal of Cell Physiology, vol. 210, no. 2, pp. 456–468, 2007. View at Google Scholar
  68. J. E. Pimanda, W. Y. Chan, I. J. Donaldson, M. Bowen, A. R. Green, and B. Gottgens, “Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer,” Blood, vol. 107, no. 12, pp. 4737–4745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. J. S. Isenberg, G. Martin-Manso, J. B. Maxhimer, and D. D. Roberts, “Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies,” Nature Review Cancer, vol. 9, no. 3, pp. 182–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Müller, K. Renger, and W. Kuhn, “Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration,” Archives of Neurology, vol. 61, no. 5, pp. 657–660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. K. M. Murphy, C. A. Nelson, and J. R. Sedy, “Balancing co-stimulation and inhibition with BTLA and HVEM,” Nature Review Immunology, vol. 6, no. 9, pp. 671–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. T. C. Cheung, M. W. Steinberg, L. M. Oborne et al., “Unconventional ligand activation of herpesvirus entry mediator signals cell survival,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 15, pp. 6244–6249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. W. J. Sandberg, B. Halvorsen, A. Yndestad et al., “Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis,” Circulation Research, vol. 104, no. 1, pp. 60–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Gavalda, H. Gutierrez, and A. M. Davies, “Developmental regulation of sensory neurite growth by the tumor necrosis factor superfamily member LIGHT,” Journal of Neuroscience, vol. 29, no. 6, pp. 1599–1607, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Yuzaki, “Cbln and C1q family proteins: new transneuronal cytokines,” Cell of Molecular and Life Science, vol. 65, no. 11, pp. 1698–1705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Iijima, K. Emi, and M. Yuzaki, “Activity-dependent repression of Cbln1 expression: mechanism for developmental and homeostatic regulation of synapses in the cerebellum,” Journal of Neuroscience, vol. 29, no. 17, pp. 5425–5434, 2009. View at Publisher · View at Google Scholar · View at Scopus